Australia

New Zealand Approves MDMA Therapy for PTSD Patients

Is this a lifeline for patients failed by other treatments or an experiment sold as medicine?

SEP 5·Updated SEP 7

New Zealand Approves MDMA Therapy for PTSD Patients

Story

Above: A dose of MDMA in the office of Dr. Michael Mithoefer, Mount Pleasant, South Carolina, on Aug. 24, 2017. Image credit: Travis Dove/Washington Post/Getty Images

The Facts

Two New Zealand psychiatrists won approval Friday from the medicines regulator Medsafe to prescribe pharmaceutical-grade MDMA to adults with post-traumatic stress disorder, an option for patients whose symptoms have not responded to conventional therapies.
Ministry of Health New Zealand
The approval makes New Zealand the second country to permit the drug's clinical use for PTSD, after Australia allowed authorized psychiatrists to provide MDMA-assisted psychotherapy in July 2023.
RNZ
EuroNews
Associate Health Minister David Seymour said PTSD "ruins lives and is difficult to treat" and that MDMA can be effective through psychedelic-assisted therapy. He said recent changes align New Zealand's settings with Australia's.
NZ Herald
1 News
MDMA remains an unapproved medicine in New Zealand, and the decision does not approve a specific product. Patients must be 18 or older, undergo a clinical assessment and receive treatment in the prescriber's clinic, with no take-home doses.
The Guardian
1 News
The two approved clinicians are Wellington's Dr. Gary Wynn, who specializes in PTSD and trauma, and Auckland's Dr. Tom Paterson, who specializes in addiction. They said they spent more than a year working through the regulatory process.
Ministry of Health New Zealand
RNZ
The approval draws on Phase 3 trials by the Multidisciplinary Association for Psychedelic Studies, though the U.S. Food and Drug Administration rejected the therapy in 2024, citing insufficient evidence of safety and effectiveness.
EuroNews
The Guardian

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Pro-government narrative

PTSD wrecks lives and existing treatments too often fail, so opening a careful door to pharmaceutical-grade MDMA is a win for suffering patients. Only two vetted psychiatrists can prescribe it, dosing happens in clinic under a full treatment plan and nobody takes pills home. Red tape should never be the reason Kiwis are denied a treatment that works.

New Zealand Government

Government-critical narrative

The evidence for MDMA-assisted therapy simply isn't there yet, and rolling it out to patients ahead of the science is reckless. The FDA rejected it over flawed study design and missing data, three supporting papers were retracted over data integrity, and the strongest trials show little real effect. Desperate patients deserve proven care, not an experiment sold as medicine.